

PTO/SB/21 (09-04)
 Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

0114-05

IFW

MAIL DATE CANCELED

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Patent & Trademark Office

Application Number	10/701,012
Filing Date	November 4, 2003
First Named Inventor	Muthiah Manoharan
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)
Total Number of Pages in This Submission	15


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Forms PTO/SB/08a and PTO/SB/08b (10 pp.); Copies of (61) Cited References Enclosed.
<div style="border: 1px solid black; padding: 2px; margin-bottom: 5px;">Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Isis Pharmaceuticals, Inc.		
Signature	<i>Robert S. Andrews</i>		
Printed name	Robert S. Andrews		
Date	1/13/2005	Reg. No.	44,508

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature	<i>Kemlyn Evans</i>		
Typed or printed name	Kemlyn Evans	Date	1/13/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



APPLICATION NUMBER: 10/701,012
FILING DATE: November 4, 2003
FIRST NAMED INVENTOR: Muthiah Manoharan
ART UNIT: 1634
EXAMINER NAME: J. J. Zara
ATTORNEY DOCKET NUMBER: ISIC0010-101 (CHEM0004US.P1)
TITLE: CROSS-LINKED OLIGOMERIC
COMPOUNDS AND THEIR USE IN GENE
MODULATION

I certify that this communication is being deposited with the U.S. Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 utilizing the "Express Mail Post Office to Addresses" service under Mailing Label No. EL07121467US on the date shown below:

Dated: 1-13-05 By: Robert S. Andrews
Robert S. Andrews, Reg. No. 44,508

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
Under 37 C.F.R. §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 C.F.R. §§ 1.56 and 1.97-98, enclosed herewith is PTO Forms PTO/SB/08A and PTO/SB/08B listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred;
- ☐ before the mailing of a first official action after filing of a request for continued examination (RCE) under 37 C.F.R. § 1.114;
- ☐ after three months of the filing date of this national application or the date of entry of the national stage in an international application, or after the mailing date of the first official action on the merits, whichever event last occurred, but before that mailing date of the first office action to occur of either: (1) a final action under 37 C.F.R. § 1.113; or (2) an action that otherwise closes prosecution in the application, and:
- ☐ attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for submission of this Information Disclosure Statement under 37 C.F.R. § 1.97(c); OR
- ☐ Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:
- ☐ each item of the information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement;
- OR
- ☐ no item of information contained in this Information Disclosure Statement was cited in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this Statement.
- ☐ on or before the payment of the issue fee but after the mailing date of the first to occur of either: (1) a final action under 37 C.F.R. § 1.113; (2) a notice of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes prosecution in the application, and:

☐ Applicant certifies pursuant to 37 C.F.R. § 1.97(e) that:

☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

OR

☐ no item of information contained in this Information Disclosure Statement was cited in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Statement. AND

☐ attached hereto is the fee set forth under 37 C.F.R. § 1.17(p) for submission of this Information Disclosure Statement under 37 C.F.R. § 1.97(c); OR

☐ after the payment of the issue fee. Applicant requests that the information contained in this Information Disclosure Statement be placed in the file according to 37 C.F.R. § 1.97(i), although the information may not be considered by the USPTO.

☒ Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

☐ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. _____, filed on _____, and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 C.F.R. § 1.98(d).

☒ This application was filed after June 30, 2003. Therefore, pursuant to the waiver of the requirements under 37 C.F.R. § 1.98(a)(2)(i), copies of each U.S. Patent and each U.S. Patent Application Publication are not required to be submitted. Copies of any foreign patent documents and non-patent literature cited herein are enclosed.

☐ Each item of information contained in this Information Disclosure Statement was cited in the communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 C.F.R. § 1.56 (c) more than thirty days prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.704(d).

☒ Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectively Submitted,

Robert S. Andrews

Robert S. Andrews
Registration No.: 44,508
Isis Pharmaceuticals, Inc.
2292 Faraday Ave.
Carlsbad, CA 92008

Dated: 1-13-05



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 10

Complete if Known

Application Number	10/701,012
Filing Date	November 4, 2003
First Named Inventor	Muthiah Manoharan
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	US-5,898,031	04-27-1999	CROOKE	
	AB	US- 6,107,094	08-22-2000	CROOKE	
	AC	US- 5,543,507	08-06-1996	COOK ET AL.	
	AD	US- 6,005,093	12-21-1999	WOOD ET AL.	
	AE	US- 5,082,934	01-21-1992	SABA ET AL.	
	AF	US- 6,406,850	06-18-2002	VOLKERS ET AL.	
	AG	US- 6,303,799	10-16-2001	CHENG ET AL.	
	AH	US- 6,232,463	05-15-2001	COOK ET AL.	
	AI	US- 6,143,877	11-07-2000	MEYER ET AL.	
	AJ	US- 6,072,046	06-06-2000	REED ET AL.	
	AK	US- 5,824,796	10-20-1998	PETRIE ET AL.	
	AL	US- 5,811,534	09-22-1998	COOK ET AL.	
	AM	US- 5,767,259	06-16-1998	ALBAGLI ET AL.	
	AN	US- 5,719,271	02-17-1998	COOK ET AL.	
	AO	US- 5,714,360	02-03-1998	SWAN ET AL.	
	AP	US- 5,681,941	10-28-1997	COOK ET AL.	
	AQ	US- 5,659,022	08-19-1997	KUTYAVIN ET AL.	
	AR	US- 4,826,967	05-02-1989	GLASS	
	AS	US- 4,123,610	10-31-1978	SUMMERTON ET AL.	
	AT	US- 2002/0012915	01-31-2002	VOLKERS ET AL.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	AU	WO01/48183	07-05-2001	DEVGEN NV		
	AV	WO00/44895	08-03-2000	KREUTZER		
	AW	WO00/49035	08-24-2000	GEN HOSP.		
	AX	WO00/63364	10-26-2000	AMER. HOME PRODUCTS		
	AY	WO01/36641	05-25-2001	CHIRON CORP		
	AZ	WO01/36646	05-25-2001	CANCER RES. CAMPAIGN		
	BA	WO99/32619	07-01-1999	CARNEGIE INST OF WASH.		
	BB	WO00/44914	08-03-2000	MED. COLLEGE OF GEORGIA		
	BC	WO01/29058	04-26-2001	UNIV. OF MASS.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	10
-------	---	----	----

Complete if Known

Application Number	10/701,012
Filing Date	November 4, 2003
First Named Inventor	Muthiah Manoharan
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	BD	US- 5,688,941	11-18-1997	COOK ET AL.	
	BE	US- 5,714,166	06-06-1996	TOMALIA ET AL.	
	BF	US- 6,153,737	11-28-2000	MANOHARAN	
	BG	US- 6,172,208	01-09-1991	COOK	
	BH	US- 6,300,319	10-09-2001	MANOHARAN	
	BI	US- 6,335,434	01-01-2002	GUZAEV ET AL.	
	BJ	US- 6,335,437	01-01-2002	MANOHARAN	
	BK	US- 6,395,437	05-28-2002	WOLLESEN	
	BL	US- 6,444,486	09-03-2002	KWAK ET AL.	
	BM	US- 6,486,308	11-26-2002	KUTYAVIN	
	BN	US- 6,525,031	02-25-2003	MANOHARAN	
	BO	US- 6,528,631	03-04-2003	COOK ET AL.	
	BP	US- 6,559,279	05-06-2003	MANOHARAN ET AL.	
	BQ	US-5,272,250	12-21-1993	SPIELVOGEL	
	BR	US- 5,292,873	03-08-1994	ROKITA ET AL.	
	BS	US- 5,317,098	03-31-1994	SHIZUYA ET AL.	
	BT	US- 5,371,241	12-06-1994	BRUSH	
	BU	US- 5,391,723	02-21-1995	PRIEST	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)				
	BV	WO01/75164	10-11-2001	WHITEHEAD INST.		
	BW	WO91/10671	07-25-1991	ISIS PHARM.		
	BX	WO96/28438	09-19-1996	NAXCOR		
	BY	WO93/07883	04-29-1993	ISIS PHARM.		

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/701,012
				Filing Date	November 4, 2003
				First Named Inventor	Muthiah Manoharan
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)
Sheet	3	of	10		

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	BZ	US- 5,416,203	05-16-1995	LETSINGER ET AL.	
	CA	US- 5,451,463	09-19-1995	NELSON ET AL.	
	CB	US- 5,510,475	04-23-1996	AGRAWAL ET AL.	
	CC	US- 5,512,667	04-30-1996	REED ET AL.	
	CD	US- 5,514,785	05-07-1996	VAN NESS ET AL.	
	CE	US- 5,565,552	10-15-1996	MAGDA ET AL.	
	CF	US- 5,567,810	10-22-1996	WEIS ET AL.	
	CG	US- 5,574,142	11-12-1996	MEYER ET AL.	
	CH	US- 5,585,481	12-17-1996	ARNOLD ET AL.	
	CI	US- 5,587,371	12-24-1996	SESSLER ET AL.	
	CJ	US- 5,595,726	01-21-1997	MAGDA ET AL.	
	CK	US- 5,597,696	01-28-1997	LINN ET AL.	
	CL	US- 5,599,923	02-04-1997	SESSLER ET AL.	
	CM	US- 5,599,928	02-04-1997	HEMMI ET AL.	
	CN	US- 5,672,662	09-30-1997	HARRIS ET AL.	
	CO	US- 4,587,044	05-06-1986	MILLER ET AL.	
	CP	US- 4,605,735	08-12-1986	MIYOSHI ET AL.	
	CQ	US- 4,667,025	05-19-1987	MIYOSHI ET AL.	

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/701,012
				Filing Date	November 4, 2003
				First Named Inventor	Muthiah Manoharan
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)
Sheet	4	of	10		

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	CR	US- 4,762,779	08-09-1988	SNITMAN	
	CS	US- 4,789,737	12-06-1988	MIYOSHI ET AL.	
	CT	US- 4,824,941	04-25-1989	GORDON ET AL.	
	CU	US- 4,835,263	05-30-1989	NGUYEN ET AL.	
	CV	US- 4,876,335	10-24-1989	YAMANE ET AL.	
	CW	US- 4,904,582	02-27-1990	TULLIS	
	CX	US- 4,958,013	09-18-1990	LETSINGER	
	CY	US- 5,082,830	01-21-1992	BRAKEL ET AL.	
	CZ	US- 5,112,963	05-12-1992	PIELES ET AL.	
	DA	US- 5,214,136	05-25-1993	LIN ET AL.	
	DB	US- 5,149,782	09-22-1992	CHANG ET AL.	
	DC	US- 5,245,022	09-14-1993	WEIS ET AL.	
	DD	US- 5,254,469	10-19-1993	WARREN III ET AL.	
	DE	US- 5,258,506	11-02-1993	URDEA ET AL.	
	DF	US- 5,262,536	11-16-1993	HOBBS ET AL.	
	DG	US- 3,687,808	08/29/1972	MERIGAN et al.	
	DH	US- 6,395,492	05-28-2002	MANOHARAN ET AL.	
	DI	US- 4,828,979	05-09-1989	KLEVAN ET AL.	
	DJ	US- 4,948,882	08-14-1990	RUTH	
	DK	US- 5,218,105	06-08-1993	COOK ET AL.	

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 10

Complete if Known

Application Number	10/701,012
Filing Date	November 4, 2003
First Named Inventor	Muthiah Manoharan
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	DL	US- 5,525,465	06-11-1996	HARALAMBIDIS	
	DM	US- 5,541,313	07-30-1996	RUTH	
	DN	US- 5,545,730	08-13-1996	URDEA ET AL.	
	DO	US- 5,552,538	09-03-1996	URDEA ET AL.	
	DP	US- 5,578,717	11-26-1996	URDEA ET AL.	
	DQ	US- 5,580,731	12-03-1996	CHANG ET AL.	
	DR	US- 5,591,584	01-07-1997	CHANG ET AL.	
	DS	US- 5,109,124	04-28-1992	RAMACHANDRAN	
	DT	US- 5,118,802	06-02-1992	SMITH ET AL.	
	DU	US- 5,138,045	08-11-1992	COOK ET AL.	
	DV	US- 5,414,077	05-09-1995	LIN ET AL.	
	DW	US- 5,486,603	01-23-1996	BUHR	
	DX	US- 5,512,439	04-30-1996	HORNES ET AL.	
	DY	US- 5,578,718	11-26-1996	COOK	
	DZ	US- 5,608,046	03-04-1997	COOK ET AL.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 10

Complete if Known

Application Number	10/701,012
Filing Date	November 4, 2003
First Named Inventor	Muthiah Manoharan
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EA	SUMMERTON, J., "Sequence-Specific Crosslinking Agents for Nucleic Acids: Design and Functional Group Testing," <i>J. Theor. Biol.</i> (1979) 78:61-75.	
	EB	MEYER, Jr., R.B., et al., "Efficient, Specific Cross-Linking and Cleavage of DNA by Stable, Synthetic Complementary Oligodeoxynucleotides," <i>J. Am. Chem. Soc.</i> (1989) 111(22):8517-8519.	
	EC	WEBB, T. R., et al., "Hybridization triggered cross-linking of deoxyoligonucleotides," <i>Nucleic Acids Res.</i> (1986) 14(19):7661-7674.	
	ED	MATTEUCCI, M. D., et al., "Synthesis and Crosslinking Properties of a Deoxyoligonucleotide Containing N ⁶ ,N ⁶ -Ethanodeoxyadenosine," <i>Tetrahedron Lett.</i> (1987) 28(22):2469-2472.	
	EE	FERENTZ, A. E., et al., "Disulfide Cross-Linked Oligonucleotides," <i>J. Am. Chem. Soc.</i> (1991) 113(10):4000-4002.	
	EF	MANOHARAN, M., "Designer Antisense Oligonucleotides: Conjugation Chemistry and Functionality Placement," <i>Antisense Research and Applications</i> , Crooke and LeBleu, eds., CRC Press Boca Raton, FL, 1993, pp 303-349	
	EG	CARMELL, M.A., et al., "The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis," <i>Gene Dev.</i> (2002) 16(21):2733-2742.	
	EH	LIN, K.-Y., et al., "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acids," <i>J. Am. Chem. Soc.</i> (1998) 120(33):8531-8532.	
	EI	FLANAGAN, W. M., et al., "Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide," <i>Nature Biotechnol.</i> (1999) 17(1):48-52.	
	EJ	MANOHARAN, M., "Oligonucleotide Conjugates in Antisense Technology," <i>Antisense Drug Technology, Principles, Strategies and Applications</i> , S.T. Crooke, ed., Dekker, Inc., 2001, pp 391-467.	
	EK	MANOHARAN, M., "Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery, and Mechanism of Action," <i>Antisense Nucleic Acid Drug Dev.</i> (2002) 12(2):103-128.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

10

Complete if Known

Application Number	10/701,012
Filing Date	November 4, 2003
First Named Inventor	Multiah Manoharan
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EL	MARTINEZ, J., et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> (2002) 110:563-574.	
	EM	BOUTLA, A., et al., "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in <i>Drosophila</i> ," <i>Curr. Biol.</i> (2001) 11:1776-1780.	
	EN	SCHWARZ, D. S., et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Mol. Cell.</i> (2002) 10:537-548.	
	EO	CHIU, Y.-L., et al., "RNAi in Human Cells: Basic Structural and Functional Features of SMall Interfering RNA," <i>Mol. Cell</i> (2002) 10:549-561.	
	EP	LIN, M., et al., "Inhibition of collagenase type I expression by psoralen antisense oligonucleotides in derman fibroblasts," <i>FASEB J.</i> (1995) 9(13):1371-1377.	
	EQ	MARUENDA, H., et al., "Antisense Sequence-Directed Cross-Linking of DNA Oligonucleotides by Mitomycin C," <i>Bioconj. Chem.</i> (1996) 7(5):541-544.	
	ER	MARUENDA, H., et al., "Antisense sequence-directed cross-linking of RNA oligonucleotides by mitomycin," <i>Anti-Cancer Drug Design</i> (1997) 12:473-479.	
	ES	HU, N., et al., "Design, Synthesis, and Evaluation of Mitomycin-Tethered Phosphorothioate Oligodeoxynucleotides," <i>Bioconj. Chem.</i> (1996) 7(6):659-669.	
	ET	COHEN, G.L., et al., "Sequence Dependent Binding of <i>cis</i> -Dichlorodiammineplatinum(II) to DNA," <i>J. Am. Chem. Soc.</i> (1980) 102(7):2487-2488.	
	EU	GRINEVA, N. I., et al., "Complementarily Addressed Modification of rRNA with p-(Chloroethylmethylamino)benzylidene Hexanucleotides," <i>FEBS Lett.</i> (1973) 32(2):351-355.	
	EV	SUMMERTON, J., et al., "Sequence-specific Crosslinking Agents for Nucleic Acids," <i>J. Mol. Biol.</i> (1978) 122(2):145-162.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known

Application Number	10/701,012
Filing Date	June 26, 2003
First Named Inventor	Muthiah Manoharan
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EW	TUSCHL, T., et al., "Targeted mRNA degradation by double-stranded RNA in vitro," <i>Genes Dev.</i> (1999) 13(24):3191-3197.	
	EX	ELBASHIR, S. M., et al., "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes Dev.</i> (2001) 15(2):188-200.	
	EY	ELBASHIR, S. M., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> (2001) 411(6836):494-498.	
	EZ	LIPARDI, C., et al., "RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs," <i>Cell</i> (2001) 107:297-307.	
	FA	NISHIKURA, K., "A Short Primer on RNAi: RNA-Directed RNA Polymerase Acts as a Key Catalyst," <i>Cell</i> (2001) 107:415-418.	
	FB	SIJEN, T., et al., "On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing," <i>Cell</i> (2001) 107:465-476.	
	FC	TIJSTERMAN, M., et al., "RNA Helicase MUT-14-Dependent Gene Silencing Triggered in <i>C. elegans</i> by Short Antisense RNAs," <i>Science</i> (2002) 295(5555):694-697.	
	FD	ELBASHIR, S. M., et al., "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate," <i>EMBO J.</i> (2001) 20(23):6877-6888.	
	FE	PARRISH, S., et al., "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Mol. Cell.</i> (2000) 6:1077-1087.	
	FF	MELLITZER, G., et al., "Spatial and temporal 'knock down' of gene expression by electroporation of double-stranded RNA and morpholinos into early postimplantation mouse embryos," <i>Mech. Devel.</i> (2002) 118(1-2):57-63.	
	FG	BASS, B. L., et al., "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> (2000) 101:235-238.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 09 Of 10

Complete if Known

Application Number	10/701,012
Filing Date	November 4, 2003
First Named Inventor	Muthiah Manoharan
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	FH	WAGNER, D., et al., "Preparation and Synthetic Utility of Some Organotin Derivatives of Nucleosides," <i>J. Org. Chem.</i> (1974) 39(1):24-30.	
	FI	NAPOLI, C., et al., "Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes <i>in trans</i> ," <i>Plant Cell</i> (1990) 2:279-289.	
	FJ	JORGENSEN, R. A., et al., "Chalcone synthase cosuppression phenotypes in petunia flowers: comparison of sense vs. antisense constructs and single-copy vs. complex T-DA sequences," <i>Plant. Mol. Biol.</i> (1996) 31:957-973.	
	FK	COGONI, C., et al., "Post-transcriptional gene silencing across kingdoms," <i>Curr. Opin. Genes Dev.</i> (2000) 10(6):638-643.	
	FL	GURA, T., "A silence that speaks volumes," <i>Nature</i> (2000) 404:804-808.	
	FM	GUO, S., et al., " <i>par-1</i> , a Gene Required for Establishing Polarity in <i>C. elegans</i> Embryos, Encodes a Putative Ser/Thr Kinase That is Asymmetrically Distributed," <i>Cell</i> (1995) 81:611-620.	
	FN	FIRE, A., et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," <i>Nature</i> (1998) 391:806-811.	
	FO	TIMMONS, L., et al., "Specific interference by ingested dsRNA," <i>Nature</i> (1998) 395:854.	
	FP	TIMMONS, L., et al., "Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in <i>Caenorhabditis elegans</i> ," <i>Gene</i> (2001) 263:103-112.	
	FQ	TABARA, H., et al., "RNAi in <i>C. elegans</i> : Soaking in the Genome Sequence," <i>Science</i> (1998) 282:430-431.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 10

Complete if Known

Application Number	10/701,012
Filing Date	June 26, 2003
First Named Inventor	Muthiah, Manoharan
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	ISIC0010-101 (CHEM0004US.P1)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	FR	MONTGOMERY, M. K., et al., "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Caenorhabditis elegans</i> ," <i>Proc. Natl. Acad. Sci. USA</i> (1998) 95(26):15502-15507.	
	FS	BRANTL, S., "Antisense-RNA Regulation and RNA Interference," <i>Biochim. Biophys. Acta.</i> (2002) 1575:15-25.	
	FT	ENDO, M., et al., "Control of A Double Helix DNA Assembly by Use of Cross-Linked Oligonucleotides," <i>J. Am. Chem. Soc.</i> (2003) 125(45):13654-13655.	
	FU	WILSON, D. S., et al., "In Vitro Selection Of Functional Nucleic Acids," <i>Annu. Rev. Biochem.</i> (1999) 68:611-647.	
	FV	International Search Report dated November 26, 2004 for International Application No. PCT/US03/34913.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.